Microcapsules containing insoluble rare ginsenosides, their preparation method and applications

The covalent cross-linked microcapsules formed by transglycosylation and transglutaminase methods encapsulate insoluble rare ginsenosides, solving the problems of low solubility in water and easy degradation in gastric acid environment. This achieves targeted release in the intestine and high bioavailability, enhances its immunomodulatory activity, and meets food-grade green manufacturing standards.

CN123059014APending Publication Date: 2026-11-10HANGZHOU RUNBEN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611350818.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies struggle to address the issues of low solubility and low bioavailability of insoluble rare ginsenosides in water, as well as their tendency to degrade easily in the acidic environment of the stomach, making it impossible to achieve targeted release into the intestines.

Method used

Using transglycosylation enzyme and transglutaminase methods, covalently cross-linked microcapsules are formed by protein wall materials and medicinal and edible active polysaccharides to encapsulate insoluble rare ginseng saponin modifiers, constructing a dense three-dimensional network to improve solubility and bioavailability, and achieving targeted release in the intestine.

Benefits of technology

It significantly improves the solubility and bioavailability of insoluble rare ginsenosides, ensures stability and targeted release in the gastrointestinal tract, enhances their immunomodulatory activity, and meets the requirements of food-grade green manufacturing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059014A_ABST
    Figure CN123059014A_ABST
Patent Text Reader

Abstract

This invention provides a microcapsule encapsulating an insoluble rare ginseng saponin modifier, its preparation method, and its application. The method utilizes a transglycosylase to obtain an insoluble rare ginseng saponin modifier via a bio-enzymatic modification process. This modifier is used as the core material, and a protein-based wall material and a medicinal and edible active polysaccharide are used as composite wall materials. Through an enzymatic covalent encapsulation system, a microcapsule encapsulating the insoluble rare ginseng saponin modifier is obtained. This method is safe, food-grade, and highly efficient, significantly improving the solubility, bioavailability, and immunomodulatory activity of the active ingredients in the prepared microcapsules. It also ensures stable gastrointestinal release, allowing for targeted release within the intestine, high bioavailability, and compliance with environmental safety regulations. This method can be applied to the treatment or prevention of tumors, metabolic diseases, or liver-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of microcapsule preparation technology, specifically to a microcapsule containing insoluble rare ginsenosides, its preparation method, and its application. Background Technology

[0002] Rare ginsenosides are a class of highly active secondary saponins obtained from ginseng, American ginseng, and other Araliaceae plants through targeted biotransformation and deep separation and purification. In their natural state, they account for less than 0.1% of the raw material, making them extremely rare "golden active ingredients" in ginseng. Compared to ordinary ginsenosides, they have smaller molecular weights and stronger biological activity. They can activate the activity of immune cells such as macrophages and NK cells, regulate immune balance, and also help inhibit tumor angiogenesis and induce cancer cell apoptosis. Furthermore, they possess multiple functions including anti-fatigue, antioxidant, cardiovascular protection, regulation of glucose and lipid metabolism, and nerve damage repair, making them a currently highly sought-after natural active ingredient. However, these components exhibit strong hydrophobicity due to the removal of sugar chains at positions C-3, C-6, or C-20, resulting in very few hydrophilic hydroxyl groups on the molecular surface. They readily aggregate and precipitate in water, and are generally poorly or insoluble in water. In their natural state, they are highly lipid-soluble, with extremely low solubility in water and physiological saline. This means they cannot be effectively dissolved in the gastrointestinal tract after oral administration, resulting in extremely low bioavailability. Under normal administration methods, they are difficult for the human body to fully absorb, and the oral absorption rate of the original saponins is less than 5%, leading to difficulties in clinical translation.

[0003] The existing technology for solving the solubility problem of rare ginsenosides often uses traditional chemical synthesis and modification methods. However, this method is often subject to harsh conditions and may introduce biotoxic catalysts or organic solvent residues, which does not meet the requirements of food grade and green manufacturing.

[0004] In addition, rare ginsenosides need to reach the small intestine to be metabolized and absorbed by the intestinal flora, thereby exerting their effects such as immune regulation and anti-tumor activity. When ordinary preparations are taken directly, most of the components are broken down and destroyed by gastric acid, and cannot reach the small intestine completely. The main method to solve this problem is ordinary physical mixing and encapsulation (such as simple emulsification). However, relying solely on weak intermolecular forces (van der Waals forces, hydrogen bonds) for binding, the microcapsule barrier is very easy to dissociate in the gastric acid (pH 1.2) environment, which will cause the active ingredients to be released prematurely and degraded or destroyed by gastric acid, and cannot achieve the complete delivery of a large amount of drug to the small intestine for targeted release.

[0005] Therefore, in order to solve the problems in the existing technology, it is urgent to develop a microcapsule that can improve the properties of insoluble rare ginsenosides, enhance immunomodulatory activity, enable the active substances to be released at specific points in the intestine with high bioavailability, and have better therapeutic effects. Summary of the Invention

[0006] To overcome the shortcomings of existing technologies, this invention provides a microcapsule encapsulating an insoluble rare ginseng saponin modifier, its preparation method, and its application. Using a transglycosylase via enzymatic modification, an insoluble rare ginseng saponin modifier is obtained. This modifier is used as the core material, and a protein-based wall material and a medicinal and edible active polysaccharide are used as composite wall materials. Through an enzymatic covalent encapsulation system, a microcapsule encapsulating the insoluble rare ginseng saponin modifier is obtained. This method is safe, food-grade, and highly efficient, significantly improving the solubility, bioavailability, and immunomodulatory activity of the active ingredients in the prepared microcapsules. It also ensures stable gastrointestinal release, allowing for targeted release within the intestine, high bioavailability, and is green, safe, and compliant with regulations. It can be applied to the treatment or prevention of tumors, metabolic diseases, or liver-related diseases.

[0007] On the one hand, the present invention provides a microcapsule encapsulating insoluble rare ginsenosides, wherein the wall material of the microcapsule includes a protein wall material and a medicinal and edible active polysaccharide.

[0008] In this invention, on the one hand, a strong covalent bond (ε-(γ-glutamyl)lysine) is formed between glutamine residues and lysine residues in the protein-based wall material through catalysis. This strong covalent bond constructs an extremely dense three-dimensional polymeric gel network, tightly locking insoluble rare saponin molecules within the crystal lattice. Simultaneously, a covalently introduced bioactive polysaccharide network, acting as a second hydrophilic shell, not only prevents the physical aggregation of microspheres but also forms a "temperature barrier" at the molecular level to resist the invasion of gastric acid hydrolytic enzymes. By using a composite wall material including protein-based wall materials and bioactive polysaccharides, a "three-dimensional network locking of biomacromolecules through covalent cross-linking" is achieved, solving the problems of degradation and drug leakage.

[0009] In some embodiments, the protein-based wall material is selected from one or more of soy protein isolate, gelatin, whey protein, albumin, pea protein, broad bean protein, and peanut protein; the medicinal and edible active polysaccharide is selected from one or more of Cordyceps sinensis polysaccharide, ginseng polysaccharide, astragalus polysaccharide, oat β-glucan, and Ganoderma lucidum polysaccharide.

[0010] Furthermore, the protein-based wall material is soy protein isolate (SPI); the medicinal and edible active polysaccharide is Cordyceps sinensis polysaccharide (CSP).

[0011] In this invention, through experimental verification, the encapsulation efficiency and bioavailability of the composite wall material of soy protein isolate and Cordyceps sinensis polysaccharide are superior to those of using protein wall materials alone or medicinal and edible polysaccharides, as well as combinations of other protein wall materials and polysaccharides. Only when soy protein isolate and Cordyceps sinensis polysaccharide are used as wall materials can the encapsulation efficiency reach 95.2% and the relative bioavailability reach 496.4% (i.e., the AUC is 4.96 times that of the original drug, which is nearly 4 times higher than that of the original drug).

[0012] In the wall material screening experiments of this invention, it was found that CPS and SPI, as composite wall materials, can improve the encapsulation efficiency of microcapsules and the bioavailability of the two active substances, CPS and ginseng rare saponin modified compounds. They are essentially non-degradable in gastric juice and exert a synergistic effect during release in intestinal juice. Using either of the two wall materials alone, or replacing them with other commonly used wall materials or medicinal and edible polysaccharides, cannot achieve this effect. This indicates that the microcapsules form a specific "wall material-core material" synergistic release model. The release process of this model includes the following stages: First stage (stomach, pH 1.2): β-(1→3)-glucan in the CPS molecule forms a tight gel layer under acidic conditions, the SPI-TG enzyme cross-linking network remains intact, the microcapsule volume shrinks, and core material leakage is effectively prevented; Second stage (upper intestine, pH 6.0-6.8) CPS molecules begin to swell, the gel layer gradually loosens, the SPI-TG enzyme network is partially degraded by trypsin, the microcapsule size gradually decreases, and rare saponins (CK, Rg3, Rh2) begin to diffuse and be released from the microcapsules. Simultaneously, the CPS wall material itself begins to dissolve, releasing immunologically active polysaccharide fragments; the third stage (lower intestine, pH...) 6.8-7.4): The microcapsules completely disintegrate, releasing all core and residual wall polysaccharides. At this point, rare saponins and CPS fragments form a high-concentration "synergistic microenvironment" in the intestinal tract. CPS promotes the intestinal absorption of rare saponins. The β-(1→3)-glucan component in CPS binds to Dectin-1 receptors on the surface of intestinal M cells, triggering endocytosis and transport. Simultaneously, it temporarily increases the permeability of tight junctions between intestinal epithelial cells (reversible opening), increasing intestinal mucosal permeability and thus promoting the transmembrane absorption of rare saponins. As a prebiotic, CPS promotes the proliferation of beneficial intestinal bacteria (such as Bifidobacteria and Lactobacillus), improving the intestinal microecological environment. These beneficial bacteria can further convert incompletely converted saponin precursors into more active rare saponins, creating a "secondary biotransformation" effect. In intestinal digestive fluids, CPS can form a mixed micelle system with bile salts and phospholipids, increasing the concentration of hydrophobic rare saponins (such as Rh2). The CPS improves water solubility and bioavailability (logP≈5.14), thereby enhancing its absorption efficiency; the oligosaccharide fragments in CPS inhibit the function of drug efflux pumps such as P-glycoprotein (P-gp), reducing the intestinal efflux of rare saponins and increasing their accumulation in intestinal epithelial cells; on the other hand, under this "synergistic microenvironment", the relative bioavailability of CPS is further improved.

[0013] Experiments on the design of the wall material and core revealed that when soy protein isolate and CPS were used as composite wall materials to encapsulate rare ginsenosides, the relative bioavailability of the two active substances significantly increased. Furthermore, both active substances (including rare ginsenosides and CPS) were simultaneously released in large quantities into the intestinal fluid, indicating that they can synergistically exert their effects in the intestine. Additionally, the immunomodulatory activity of the microcapsules was significantly increased, suggesting that this specific "wall material-core material" synergistic release model creates a high-concentration "synergistic microenvironment" in the intestinal tract after simultaneous release. While effectively promoting immunomodulatory activity, the aforementioned beneficial effects could not be achieved by using rare ginsenosides and soy protein isolate as wall materials and CPS as the core, or by using rare ginsenosides, CPS, and soy protein isolate as wall materials. If soy protein isolate alone was used as the wall material to encapsulate ginsenoside modifications or CPS, the relative bioavailability and immunomodulatory activity of the two active substances were lower than those of the composite wall material. Furthermore, a large amount of rare ginsenosides was released and degraded in the gastric juice stage, preventing the simultaneous large-scale release of both active substances in the intestinal fluid. This indicates that in the unique "wall material-core material" synergistic release model formed by soy protein isolate and CPS as the composite wall material and rare ginsenoside modifications as the core, CPS promotes the intestinal absorption of rare saponins, while the rare ginsenoside modifications promote the intestinal absorption of CPS and enhance the immunomodulatory activity of the microcapsules.

[0014] In some embodiments, the wall material in the microcapsules is encapsulated with insoluble rare ginsenosides via enzymatic covalent cross-linking by transglutaminase.

[0015] This invention experimentally verifies that by utilizing TG enzyme to catalyze the formation of ε-(γ-glutamyl)lysine covalent isopeptide bonds between soy protein isolate molecules, an extremely dense covalent network is constructed in three-dimensional space, capable of resisting attack by gastric acid and pepsin. Once in the small intestine, trypsin's selective hydrolysis of the protein backbone causes the network to dissociate, thereby achieving a precise delivery effect of "zero leakage into the stomach and complete targeted release into the intestine," effectively avoiding unnecessary degradation of active ingredients in the stomach.

[0016] In some embodiments, the insoluble ginsenoside modification embedded in the microcapsule is formed by transglycosylase catalyzing the attachment of a group on a glycosyl donor to the ginsenoside.

[0017] By using transglycosylation enzymes, without destroying the core active nucleus (dammarane-type tetracyclic triterpenoid) of rare saponins, glucose groups on the donor are catalyzed and covalently linked to the residual sugar chain ends of insoluble saponins in a directional and gentle manner. The newly introduced glucose groups (hydrophilic groups) extend outward in the molecular spatial conformation, breaking the tight hydrophobic stacking between the original rare saponin molecules and forming a "hydration film" on the molecular periphery. This fundamentally improves its dispersion and solubility in an aqueous environment, resulting in a significant increase in the solubility of chemically modified insoluble ginseng rare saponins.

[0018] Furthermore, the transglycosylase is selected from one or more of cyclodextrin glucosyltransferase, starch sucrase, or β-glucosidase.

[0019] This invention experimentally verifies that, through the mild catalysis of Aspergillus niger β-glucosidase, hydrophilic glucose groups were successfully covalently introduced into specific sites of the CK molecule. The newly introduced glycosyl group significantly weakens the hydrophobic association between saponin molecules and constructs a stable hydrophilic hydration layer on the molecule's periphery, thereby increasing solubility by 167 times. In the transglycosylation enzyme screening experiments of this invention, it was found that using this enzyme for enzymatically catalyzed targeted glycosylation produces more glycosylated products and generates fewer impurities, demonstrating superior performance compared to other enzymes.

[0020] On the other hand, the present invention provides a method for preparing microcapsules encapsulating insoluble rare ginsenosides, characterized in that the preparation method includes the following steps: (a) Enzymatic directional glycosylation: Using transglycosylase, groups on the glycosyl donor are catalyzed to attach to ginsenosides, forming insoluble rare ginsenoside modified products; (b) TG enzymatic covalent crosslinking: After high-speed shearing emulsification of protein wall materials and medicinal and edible active polysaccharides, insoluble rare ginseng saponin modifiers are encapsulated by transglutaminase covalent crosslinking.

[0021] Furthermore, the transglycosylation enzyme is selected from one or more of cyclodextrin glucosyltransferase, amylase, or β-glucosidase; the protein wall material is soybean protein isolate; and the medicinal and edible active polysaccharide is Cordyceps sinensis polysaccharide.

[0022] Furthermore, the preparation method includes the following steps: Enzymatic chemical modification Substrate preparation Weigh 10.0 g of high-purity ginseng rare saponins and dissolve them in 100 mL of 20% (v / v) food-grade ethanol aqueous solution; then add 30 g of maltodextrin (DE value 10~15) as a glycosyl donor, add 800 mL of phosphate buffer (50 mM, pH 6.5), place in a reaction vessel and stir at 150 rpm until homogeneous to form a milky white suspension reaction system.

[0023] (2) Enzyme-catalyzed reaction Add Aspergillus niger β-glucosidase to the reaction vessel at a concentration of 15 U / g based on the mass of the substrate CK. Adjust the system temperature to 45°C and react in the dark for 16 hours.

[0024] (3) Inactivation and purification After the reaction was completed, the reaction solution was heated to 90°C and held for 10 minutes to completely denature and inactivate the enzyme. After cooling to room temperature, the reaction solution was centrifuged at 8000 rpm for 15 minutes to remove unreacted insoluble matter. The supernatant was subjected to column chromatography using a macroporous adsorption resin (D101 type). Unreacted maltodextrin and inorganic salts were first removed by elution with 3 column volumes of distilled water, followed by elution with 60 (v / v) ethanol, and the target glycosylated modified ginsenoside CK fraction was collected. The insoluble rare ginsenoside modified product was obtained by concentration under reduced pressure and freeze-drying.

[0025] Enzymatic physical encapsulation Wall and core emulsification Weigh 15g of soy protein isolate (SPI) and 5.0g of Cordyceps sinensis polysaccharide and dissolve them in 400mL of deionized water. Stir at 45°C for 2 hours to prepare a composite wall material solution. Slowly add 5g of product A prepared in step 1 to the wall material solution as a core material. Place the mixture in a high-shear emulsifier and emulsify at 12000rpm for 8 minutes to obtain a uniformly dispersed O / W type primary emulsion system.

[0026] Enzymatic covalent crosslinking Adjust the pH of the emulsion to 7.2 using 0.1M NaOH solution. Add transglutaminase (TG enzyme, specific activity 100 U / g) to the emulsion at a rate of 2.0 wt% (0.3 g) of the soybean protein isolate. Incubate at 42°C with gentle stirring for 2 hours to promote the formation of ε-(γ-glutamyl)lysine covalent isopeptide bonds between glutamine and lysine residues in the protein, thus trapping and locking the core material.

[0027] Dry into powder The cross-linked slurry was fed into a spray dryer for drying. The drying process parameters were set as follows: inlet air temperature 150℃, outlet air temperature 80℃, and feed flow rate 15mL / min. The microcapsule powder collected from the bottom of the drying tower yielded the enzymatically covalently cross-linked microcapsules.

[0028] Furthermore, the present invention provides the use of the above-described microcapsules, or microcapsules prepared by the above-described preparation method, in improving the performance of active ingredients, wherein the improved performance includes: (a) Increased solubility of rare ginsenosides; (b) The bioavailability of rare ginsenosides and cordyceps polysaccharides in vivo is improved; (c) Rare ginsenosides and cordyceps polysaccharides are released upon reaching the small intestine and colon.

[0029] In another aspect, the present invention provides the use of the above-mentioned microcapsules or microcapsules prepared by the above-mentioned preparation method in the preparation of drugs that enhance immunomodulatory activity.

[0030] The modified ginseng rare saponins and CPS in the microcapsules work together to enhance immunomodulatory activity. On one hand, CPS promotes the intestinal absorption of rare saponins. The β-(1→3)-glucan component in CPS can bind to Dectin-1 receptors on the surface of intestinal M cells, triggering endocytosis and transport. Simultaneously, it temporarily increases the permeability of tight junctions between intestinal epithelial cells (reversible opening), increasing intestinal mucosal permeability and thus promoting the transmembrane absorption of rare saponins. As a prebiotic, CPS can promote the proliferation of beneficial intestinal bacteria (such as Bifidobacteria and Lactobacillus), improving the intestinal microecological environment. These beneficial bacteria can further convert incompletely converted saponin precursors into more active rare saponins, forming a "secondary biotransformation" effect. In intestinal digestive fluids, CPS can form a mixed micelle system with bile salts and phospholipids, increasing the absorption of hydrophobic rare saponins (such as Rh2, ...). The water solubility and bioavailability of CPS (logP≈5.14) enhance its absorption efficiency; the oligosaccharide fragments in CPS inhibit the function of drug efflux pumps such as P-glycoprotein (P-gp), reducing the intestinal efflux of rare saponins and increasing their accumulation in intestinal epithelial cells; on the other hand, the mechanism by which rare saponins, especially CK and Rg3, enhance the immunomodulatory activity of CPS is that microcapsules can upregulate the expression of Toll-like receptor 4 (TLR4), complement receptor 3 (CR3), differentiation cluster 80 (CD80), and differentiation cluster 86 (CD86) on the surface of macrophages. Among them, TLR4 acts as an upstream initiator of the immune response, triggering pro-inflammatory pathways such as NF-κB by recognizing pathogen-associated molecular patterns, thus determining the initial sensitivity of immune activation; CR3 acts as the execution core of phagocytic defense, directly determining the basic clearance of immune cells by mediating the phagocytosis of pathogens after complement opsonization. Efficiency; CD86, as an early activation signal of adaptive immunity, preferentially binds to CD28 to provide the necessary co-stimulatory second signal for naive T cells, determining the initiation speed of T cell activation; CD80, as a mid-to-late stage regulatory node of immune homeostasis, preferentially binds to CTLA-4 to transmit inhibitory signals, avoiding over-activation of the immune response. From the initiation of the immune response and the execution of pathogen defense to the transmission of T cell activation signals and the negative braking of the immune response, it jointly and precisely regulates the intensity and direction of immune regulatory activity, enhances macrophage recognition and response to CPS polysaccharide molecules, and amplifies the immune signal transduction pathway; CK promotes the nuclear translocation of NF-κB by activating the MAPK signaling pathway, and Rg3 promotes the nuclear translocation of NF-κB by inhibiting the PI3K / AKT negative regulatory signal, while CPS also activates NF-κB through the Dectin-1 / Syk-CARD9 pathway.Three pathways converge at the NF-κB node, producing a significant signal amplification effect; rare saponins can enhance the maturation and antigen presentation function of dendritic cells (DCs), and the immune enhancement effect of CPS also requires the participation of DCs. The combination of the two can form a positive feedback loop of "innate immunity-adaptive immunity", significantly enhancing the overall immune response; on the other hand, the "wall material-core material" of this invention forms a synergistic release model. In the first stage (stomach, pH 1.2): β-(1→3)-glucan in CPS molecules forms a tight gel layer under acidic conditions, the SPI-TG enzyme cross-linking network remains intact, and the microcapsule volume shrinks by about 15%, effectively preventing core material leakage (release rate of only 6.8% in 2 hours); in the second stage (upper intestine, pH 6.0-6.8): CPS molecules begin to swell, the gel layer gradually loosens, the SPI-TG enzyme network is partially degraded under the action of trypsin, and the microcapsule particle size gradually decreases from 10.2 μm to 5-8 μm. Rare saponins (CK, Rg3, Rh2) begin to diffuse and be released from the microcapsules, while the CPS wall material itself also begins to dissolve, releasing immunomodulatory polysaccharide fragments; in the third stage (lower intestine, pH 6.8-7.4): the microcapsules completely disintegrate, releasing all core material and residual wall material polysaccharides. At this point, rare saponins and CPS fragments form a high-concentration "synergistic microenvironment" in the local intestine, exerting the strongest immune enhancement and anti-tumor effects through the aforementioned synergistic mechanisms.

[0031] The present invention has the following beneficial effects: 1. Significant improvement in physical properties - a leap in solubility: The saturated solubility of rare ginsenosides modified by transglycosylation enzymes in water at 25°C jumps from very slightly soluble (e.g., <10 mg / L) to over 800 mg / L. This allows insoluble rare saponins, which could only be made into solid capsules or tablets, to be directly developed into high-concentration, clear, transparent, and palatable functional beverages or oral liquids, greatly expanding their application scenarios in the food and beverage industry. 2. A leap in physiological performance - bioavailability (AUC) increased by nearly 3 to 4 times. Results: Pharmacokinetic (PK) results in rats showed that the oral bioavailability (area under the line) of modified or encapsulated rare ginsenosides increased by 2.5 to 3.8 times. This means that when consumers ingest the same dose of the product, the concentration of the "active form" that can be absorbed into the blood and exert effects such as immune regulation, anti-fatigue, and activation of cellular energy metabolism is greatly increased, resulting in "faster onset of action and lower dosage". 3. Precise Regulation of Release Behavior - Performance of Gastric Tolerance and Intestinal Targeted Release: The TG enzyme-crosslinked microcapsules maintained high integrity in simulated gastric juice (pH 1.2) (almost no leakage within 2 hours, retention rate >97%); while in simulated intestinal juice (pH 6.8, containing trypsin), due to the selective enzymatic hydrolysis of the protein network, the rare saponins in the core material and the prebiotic-like Cordyceps sinensis polysaccharides were released in situ and synergistically, avoiding potential irritation to the gastric mucosa and ensuring that the active substances could reach the small intestine and colon unharmed, precisely exerting the effects of intestinal microecological regulation and systemic immune activation; 4. Green Safety and Compliance - 100% Food-Grade Pure Green Process Performance: The entire process uses enzymatic catalysis, and the reaction conditions are a mild aqueous system (temperature 40°C, neutral pH), completely avoiding the use of harsh organic solvents and heavy metal catalysts in chemical modification methods. The product is completely free of toxic crosslinking agents or solvent residues, and 100% meets the stringent safety regulatory requirements for "Clean Label", high-end health foods, dietary supplements, and foods for special medical purposes (FSMP). 5. Enhanced Immunomodulatory Activity of Microcapsules: Microcapsules upregulate the expression of Toll-like receptor 4 (TLR4), complement receptor 3 (CR3), differentiation cluster 80 (CD80), and differentiation cluster 86 (CD86) on the surface of macrophages. TLR4 acts as an upstream initiator of the immune response, triggering pro-inflammatory pathways such as NF-κB by recognizing pathogen-associated molecular patterns, thus determining the initial sensitivity of immune activation. CR3, as the core of phagocytic defense, directly determines the basal clearance efficiency of immune cells by mediating complement-mediated opsonization of pathogens. CD86, as a precursor for adaptive immunity... Early activation signals preferentially bind to CD28 to provide the necessary co-stimulatory second signal for naive T cells, determining the initiation speed of T cell activation; CD80, as a mid-to-late stage regulatory node of immune homeostasis, preferentially binds to CTLA-4 to transmit inhibitory signals, avoiding excessive activation of the immune response. From the initiation of the immune response and the execution of pathogen defense, to the transmission of T cell activation signals and the negative braking of the immune response, they jointly and precisely regulate the intensity and direction of immune regulatory activity. The combined use of the two active substances in the microcapsule can form a positive feedback loop of "innate immunity-adaptive immunity", significantly enhancing the overall immune response. Attached Figure Description

[0032] Figure 1 A process flow diagram for encapsulating microcapsules containing enzymatically modified insoluble rare ginsenosides. Detailed Implementation

[0033] To describe the present invention more specifically, the technical solution of the present invention will be described in detail below with reference to the accompanying drawings and specific embodiments. These descriptions are merely illustrative of how the present invention is implemented and do not limit the specific scope of the invention. All materials used in this experiment are commercially available. The scope of the present invention is defined in the claims.

[0034] Example 1: Preparation of microcapsules encapsulating enzymatically modified insoluble rare ginsenosides Enzymatic chemical modification Substrate preparation Weigh 10.0 g of high-purity ginsenoside Compound K (purity 98%) and dissolve it in 100 mL of 20% (v / v) food-grade ethanol aqueous solution; then add 30 g of maltodextrin (DE value 10~15, Shandong Xiwang Sugar Industry Co., Ltd.) as a glycosyl donor, add 800 mL of phosphate buffer (50 mM, pH 6.5), place in a reaction vessel and stir evenly at 150 rpm to form a milky white suspension reaction system.

[0035] (2) Enzyme-catalyzed reaction Add Aspergillus niger β-glucosidase (Sigma-Aldrich, G4511-5KU) to the reaction vessel at a concentration of 15 U / g based on the mass of the substrate CK. Adjust the system temperature to 45°C and react in the dark for 16 hours.

[0036] (3) Inactivation and purification After the reaction was complete, the reaction solution was heated to 90°C and held for 10 minutes to completely denature and inactivate the enzyme. After cooling to room temperature, the reaction solution was centrifuged at 8000 rpm for 15 minutes to remove unreacted insoluble matter. The supernatant was subjected to column chromatography using a macroporous adsorption resin (D101 type). Unreacted maltodextrin and inorganic salts were first removed by elution with 3 column volumes of distilled water, followed by elution with 60 (v / v) ethanol, and the target glycosylated ginsenoside CK fraction was collected. After concentration under reduced pressure and freeze-drying, a white powder product A was obtained.

[0037] Enzymatic physical encapsulation Wall and core emulsification Preparation of Cordyceps sinensis polysaccharides: Dry powder of fermented Cordyceps sinensis mycelium was taken and added to deionized water at a material-to-liquid ratio of 1:30 (w / v). The mixture was extracted with hot water at 90℃ for 3 hours, and the extraction was repeated twice. The extracts were combined and concentrated under reduced pressure at 60℃ to 1 / 5 of the original volume. Three volumes of anhydrous ethanol were added to the concentrate, and the mixture was allowed to stand at 4℃ for 12 hours. The precipitate was collected by centrifugation at 4000 rpm for 15 minutes. The precipitate was deproteinized three times using the Sevag method (chloroform:n-butanol = 4:1, v / v). The aqueous phase was dialyzed through a dialysis bag (molecular weight cutoff 3500 Da) for 48 hours to remove small molecule impurities. The dialysate was freeze-dried under vacuum to obtain a white, flocculent Cordyceps sinensis polysaccharide powder. The polysaccharide content was determined to be ≥90% by the phenol-sulfuric acid method.

[0038] Weigh 15g of soy protein isolate (SPI, Linyi Shansong Biological Products Co., Ltd., food grade, protein content ≥90%) and 5.0g of Cordyceps sinensis polysaccharide, dissolve them in 400mL of deionized water, and stir at 45°C for 2 hours to obtain a composite wall material solution. Slowly add 5g of product A prepared in step 1 to the wall material solution as a core material. Place the mixture in a high-shear emulsifier and emulsify at 12000rpm for 8 minutes to obtain a uniformly dispersed O / W type colostrum system.

[0039] Enzymatic covalent crosslinking Adjust the pH of the emulsion to 7.2 using 0.1M NaOH solution. Add food-grade transglutaminase (TG enzyme, Taixing Dongsheng Biotechnology Co., Ltd., food grade, specific activity 100U / g) to the emulsion at a concentration of 2.0wt% (0.3g) of soybean protein isolate. React with gentle stirring at 42°C for 2 hours to promote the formation of ε-(γ-glutamyl)lysine covalent isopeptide bonds between glutamine and lysine residues in the protein, thus trapping and locking the core material.

[0040] Dry into powder The cross-linked slurry was fed into a spray dryer for drying. The drying process parameters were set as follows: inlet air temperature 150℃, outlet air temperature 80℃, and feed flow rate 15mL / min. The microcapsule powder collected from the bottom of the drying tower yielded the enzymatically covalently cross-linked microcapsule product (product B).

[0041] Example 2: Properties and applications of microcapsules containing enzymatically modified insoluble rare ginsenosides Experimental materials: Glycosylated modified ginsenoside CK (product A), TG enzyme cross-linked composite microcapsules, natural prototype CK technical grade cross-linked composite microcapsules, physically mixed uncross-linked microcapsules, single protein wall material cross-linked microcapsules, single polysaccharide wall material cross-linked microcapsules, and unmodified natural ginsenoside CK technical grade prepared by the method in Example 1; simulated gastric juice (SGF, containing 1% w / v pepsin, pH 1.2); simulated intestinal juice (SIF, containing 1% w / v trypsin, pH 6.8).

[0042] This embodiment focuses on examining key performance indicators of microcapsules, such as solubility, encapsulation efficiency, gastrointestinal release characteristics, pharmacokinetics, and immunomodulatory activity. For other physicochemical parameters of microcapsules, such as particle size, zeta potential, drug loading, and TG enzyme crosslinking degree, and their detection methods, please refer to the wall material screening section of Example 3.

[0043] Main instruments: High performance liquid chromatograph (HPLC, Agilent 1260, with UV detector), ultrasonic cleaner, constant temperature shaking water bath, centrifuge (12000 rpm).

[0044] solubility Experimental methods According to the sample forms in Table 1, excess powder samples were weighed and placed in 10 mL of distilled water. The samples were then shaken at 150 rpm for 24 hours in a constant temperature water bath at 25°C to reach dissolution equilibrium. Subsequently, the suspensions were centrifuged at 12000 rpm for 15 minutes. The supernatant was filtered through a 0.22 μm organic filter membrane, and the drug concentration in the supernatant was determined by HPLC. The specific HPLC procedure was as follows: an Agilent Zorbax Eclipse Plus C18 column (4.6 × 250 mm, 5 μm); mobile phase A was acetonitrile, and mobile phase B was 0.1% (v / v) phosphoric acid aqueous solution; gradient elution program: 0–10 min, 20%–40% A; 10–20 min, 40%–60% A; 20–25 min, 60%–80% A; 25–30 min, 80%–20% A; flow rate 1.0 mL / min; column temperature 30℃; detection wavelength 203 nm; linear range of the standard curve 0.5–500 μg / mL; correlation coefficient R0. 2 ≥0.999. Three parallel determinations were performed, and the average value was taken. The study investigated the improvement in solubility of each group under ambient temperature aqueous conditions.

[0045] (2) Experimental results The results of the saturated solubility of each group of microcapsules in water at 25°C are shown in Table 1.

[0046] Table 1. Results of sample solubility test

[0047] The experimental results are shown in Table 1. At 25℃, the saturated solubility of the natural prototype CK in water is extremely low, only 5.1 mg / L, exhibiting a strong hydrophobic stacking phenomenon. However, after the transglycosylation enzyme method of Example 1 of this invention, the saturated solubility of product A in water increased dramatically to 852.4 mg / L. After further encapsulating the glycosylated modified CK in TG enzyme cross-linked composite microcapsules (product B), its saturated solubility in water at 25℃ was 450.8 mg / L, lower than that of free glycosylated modified CK (852.4 mg / L). This is because after the glycosylated modified CK is encapsulated by the TG enzyme cross-linked composite wall material, most of the active molecules are physically locked inside the dense three-dimensional gel lattice formed by the SPI-CPS covalent cross-linked network and cannot freely diffuse into the aqueous phase. Therefore, this measured value reflects the amount of glycosylated modified CK released from the microcapsule matrix into the aqueous phase under oscillating equilibrium conditions, rather than the inherent solubility of the glycosylated modified CK molecules themselves. This result precisely demonstrates that the microcapsule structure effectively encapsulates and locks the core material, which is highly consistent with the gastrointestinal sustained-release characteristic of only 2.5% cumulative release rate in gastric juice over the following 2 hours. This confirms the successful encapsulation and controlled release capability of the cross-linked microcapsules for the active ingredient. Although the amount of glycosylated modified CK released from the microcapsule matrix into the aqueous phase under oscillatory equilibrium conditions is lower than that of free glycosylated modified CK, it is still far higher than the solubility of the prototype drug at 5.1 mg / L.

[0048] Encapsulation efficiency and surface free drug rate Experimental methods Three parallel samples of the same mass of drug microcapsule suspension were taken. The microcapsule precipitate was first rapidly eluted with 3 column volumes of 4°C blank sustained-release buffer. After collecting all the eluent and making up to a fixed volume, the sample was filtered through a 0.22 μm organic filter membrane and directly injected into the HPLC to obtain the surface free drug mass Cs. Subsequently, the eluted microcapsules were resuspended and loaded onto the HPLC, eluted with the same buffer, and all free drug eluents were collected, made up to a fixed volume, and filtered through a membrane. The total free drug mass Cf of the system was obtained by HPLC using the method described in Example 2. Another equal volume of the original microcapsule suspension was taken, and an equal volume of decapsulation organic solvent was added. The microcapsule wall material was completely destroyed by sonication in an ice bath for 30 minutes. After all the encapsulated drug was released, the sample was made up to a fixed volume and filtered through a membrane. The total drug mass Ct of the system was obtained by HPLC. The encapsulation efficiency was calculated by substituting the values ​​into the formulas EN%=(1-Cf / Ct)×100% and F%=(Cs / Ct)×100% to calculate the surface free drug rate.

[0049] Experimental results The actual encapsulation efficiency and surface free drug rate of each group of microcapsules are shown in Table 2.

[0050] Table 2 Results of actual encapsulation efficiency and surface free drug rate of microcapsules

[0051] Experimental results showed that when composite wall materials were added but cross-linking was not performed, the encapsulation efficiency was only 62.1%, and the surface free drug rate was 18.5%, indicating poor encapsulation effect. Using single protein wall materials or single polysaccharide wall materials for cross-linking to prepare microcapsules could significantly improve the encapsulation efficiency and reduce the surface free drug rate. When using composite wall materials for cross-linking to prepare microcapsules, the encapsulation efficiency was the highest, reaching 81.4%, and the surface free drug rate was the lowest, as low as 8.2%. This indicates that transglutaminase (TG enzyme) catalyzes the formation of covalent bonds between glutamine residues and lysine residues in soy protein isolate, constructing an extremely dense three-dimensional polymeric gel network that tightly locks insoluble rare saponin molecules inside the lattice. At the same time, the covalently introduced Cordyceps sinensis polysaccharide network acts as a second hydrophilic shell, preventing the physical aggregation of microspheres.

[0052] Simulated gastrointestinal dynamic cumulative release rate Experimental methods Following the sample formats in Table 3, each group of samples was placed in a dialysis bag (intercepting molecular weight 8000 Da) and immersed in 100 mL of simulated gastric fluid (pH 1.2), and kept at a constant temperature of 37°C and 100 rpm. At 1 hour and 2 hours, 1 mL of extradialysis fluid was aspirated, and an equal volume of gastric fluid was added. The release rates of glycosylated modified CK (detection wavelength 203 nm) and Cordyceps sinensis polysaccharide (detection wavelength 210 nm) were determined using the HPLC method described in Example 2. After 2 hours, the dialysis bag was transferred to simulated intestinal fluid (pH 6.8), and samples were aspirated again at 3 hours and 6 hours to calculate the cumulative release percentage. The dynamic release and degradation characteristics of each group under simulated gastrointestinal fluid conditions were investigated.

[0053] (2) Experimental results The release rates of each group in gastric and intestinal fluids are detailed in Tables 3 and 4 below.

[0054] Table 3. Dynamic release and degradation characteristics of glycosylated CK in simulated gastrointestinal fluid.

[0055] Table 4. Dynamic release and degradation characteristics of Cordyceps sinensis polysaccharides in simulated gastrointestinal fluid.

[0056] Experimental results showed that the TG enzyme-crosslinked composite microcapsules exhibited extremely strong structural stability in simulated gastric juice (the glycosylated modified CK showed a cumulative release of only 2.5% after 2 hours), thanks to the fact that the covalent isopeptide bonds catalyzed by TG enzyme could not be efficiently cleaved by pepsin. In simulated intestinal juice, as trypsin degraded the protein backbone, the microcapsule structure responded rapidly and released into the intestinal juice, achieving a targeted and efficient release with a cumulative release rate of 94.1% at the endpoint (6 hours). This allowed for the in-situ and synergistic release of the core material rare saponins and the prebiotic-like Cordyceps sinensis polysaccharides, while other groups could not achieve this effect. The group without TG enzyme covalent crosslinking showed a release rate as high as 28.5% in gastric juice after only 1 hour. The hourly release rate reached 46.2%, while the cumulative release rate in the simulated intestinal fluid stage (6 hours, the endpoint) was only 78.2%. This indicates that although soy protein isolate and cordyceps polysaccharide form a physical cross-linking network through hydrogen bonds, electrostatic interactions, hydrophobic interactions, and van der Waals forces, and the glycosylated CK molecule contains polyhydroxy sugar chains that may form hydrogen bonds with the hydroxyl groups of cordyceps polysaccharide, microcapsules without TG enzyme covalent cross-linking have a weaker release barrier, leading to a large release of product A in gastric juice. Furthermore, the hydrogen bonds between the sugar chains of product A and the hydroxyl groups of cordyceps polysaccharide hinder the complete release of product A in intestinal juice. These experimental results demonstrate that only microcapsules containing rare ginsenosides, formed by cross-linking with both wall material components using TG enzyme and then encapsulated, can avoid potential irritation to the gastric mucosa, ensuring that the active substances can reach the small and colon unharmed, precisely exerting their effects on intestinal microecological regulation and systemic immune activation.

[0057] As shown in Table 4, Cordyceps sinensis polysaccharides in this microcapsule system can also reduce the release in gastric juice and enhance the release in intestinal juice. The cumulative release rate in the simulated gastric juice stage (2 hours) was only 3.3%, while the cumulative release rate in the simulated intestinal juice stage (6 hours, the endpoint) reached 58.4%. Compared with group 1, the physically mixed uncrosslinked microcapsules and the single polysaccharide wall material crosslinked microcapsules had higher release in the simulated gastric juice stage and lower release in the simulated intestinal juice stage, indicating that the microcapsules formed by the composite wall material play an important role in the precise intestinal synergistic release of Cordyceps sinensis polysaccharides. In addition, the TG enzyme crosslinked composite microcapsules without encapsulating product 1 had the highest release in the gastric juice stage and the lowest release in the simulated intestinal juice stage, indicating that glycosylation modification CK also plays a crucial role in the intestinal release of Cordyceps sinensis polysaccharides. This shows that on the one hand, the microcapsule system of the composite wall material plays a role in the targeted intestinal release of the two active substances, and on the other hand, glycosylation modification CK and Cordyceps sinensis polysaccharides mutually promote the synergistic release of the two in the intestine.

[0058] Pharmacokinetic parameters Experimental methods Healthy SPF-grade SD rats were selected and randomly grouped according to body weight. A two-period self-crossover design was used, with seven washout periods of more than seven drug half-lives. Samples from each group were administered by gavage. Before the experiment, all rats were fasted for 8 hours but allowed free access to water. Plasma samples from the orbital venous plexus were collected before administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours after administration. The plasma concentrations at each time point were quantitatively determined using a validated LC-MS / MS method. The measured peak concentration Cmax and peak time Tmax were directly read using a non-compartmental model of DAS pharmacokinetic software. Logarithmic linear regression was performed on the terminal elimination rate constant β at 3-4 consecutive concentration points at the end of the elimination phase, and the elimination half-life t1 / 2 was calculated. The AUC0→t was obtained by summing the values ​​using the trapezoidal method, and then extrapolated to obtain AUC0→∞. After dose correction, the relative bioavailability was finally calculated.

[0059] Experimental results The pharmacokinetic parameters of rare ginsenosides in each group are shown in Table 5.

[0060] Table 5. Pharmacokinetic parameters of rare ginsenosides

[0061] The pharmacokinetic parameters of Cordyceps sinensis polysaccharides in each group are shown in Table 6.

[0062] Table 6 Pharmacokinetic parameters of Cordyceps sinensis polysaccharides

[0063] Experimental results showed that the relative bioavailability of rare ginsenosides in the TG enzyme-crosslinked composite microcapsule was 496.4% of that of the original drug, and the bioavailability of Cordyceps sinensis polysaccharide in the microcapsule system was 288.4% of that of Cordyceps sinensis polysaccharide taken alone. Compared with other groups, the bioavailability of the two active substances was the highest. The experimental results of other groups showed that the significant increase in the bioavailability of the two active substances was achieved by the combined effect of the modification of the original drug (the presence of glycosylation modification CK) and the formation of microcapsules by crosslinking the composite wall material composed of soy protein isolate and Cordyceps sinensis polysaccharide through TG enzyme. The absence of any one of these conditions would not have achieved this effect. This indicates that only by modifying and encapsulating the product using the method of this invention can a significant increase in relative bioavailability be achieved. This results in a significant increase in the concentration of the "active form" that can be absorbed into the blood and exert effects such as immune regulation, anti-fatigue, and activation of cellular energy metabolism when the same dose of product is ingested.

[0064] Regulation of immune activity Experimental methods Primary peritoneal macrophages were induced and enriched in 6-8 week old SPF-grade C57BL / 6 mice using the intraperitoneal injection of mercaptoacetate broth. After aseptic irrigation of the peritoneal cavity to collect cells, they were cultured in RPMI 1640 complete medium containing 10% fetal bovine serum and purified by adhesion in a 37°C, 5% CO2 incubator for 2 hours. Non-adherent cells were discarded to obtain primary macrophages with a purity of over 95%. A blank control group (primary macrophages cultured and purified in RPMI 1640 complete medium containing 10% fetal bovine serum), a positive control group (with added LPS), and experimental groups (all experimental groups were simultaneously added with the same final concentration of LPS) were set up. After corresponding treatments, cells were collected, resuspended, and the concentration was adjusted to 1×10⁶. 6 The cells were added sequentially at a rate of 100 cells / mL to the fluorescently labeled anti-TLR4, anti-CR3, anti-CD80, and anti-CD86 monoclonal antibodies that had been validated in previous experiments. The cells were incubated at 4°C in the dark for 30 minutes. After washing twice with pre-cooled PBS staining buffer containing 5% fetal bovine serum to remove unbound antibodies, and after removing dead cells by adding 7-AAD live cell dye, the target population of CD11b+F4 / 80+ macrophages was selected using flow cytometry. More than 10,000 effective cells were collected from each tube, and the mean fluorescence intensity (MFI) of TLR4 and CR3 and the percentage of positive cells for CD80 and CD86 were directly read.

[0065] Table 7 Grouping of Immunomodulatory Activity Assessment

[0066] Experimental results The results of TLR4 / CR3 / CD80 / CD86 expression detection on the surface of macrophages are shown in Table 8.

[0067] Table 8. Results of TLR4 / CR3 / CD80 / CD86 expression detection on macrophage surface

[0068] The experimental results are shown in Table 8. When glycosylated modified CK (product A) or Cordyceps sinensis polysaccharide was used alone for immunomodulatory activity detection, glycosylated modified CK (especially CK aglycone) could simultaneously activate multiple pathways such as TLR4 / NF-κB and MAPK, with a wider signal coverage. Therefore, when used alone, CK was slightly higher than Cordyceps sinensis polysaccharide. Cordyceps sinensis polysaccharide mainly achieves the innate immune pathway through TLR4 / CR3. Moreover, without microencapsulation protection, it may be partially degraded or non-specifically bound to the culture medium components in the cell culture system, and the actual effective concentration is lower than the theoretical value. The TG enzyme-crosslinked composite microcapsule group (product B) showed the highest expression levels of TLR4, CR3, CD80, and CD86 across all four indicators. The absence of glycosylation modification (CK, product A), the absence of the composite wall material composed of soybean protein isolate and Cordyceps sinensis polysaccharide, and the absence of TG enzyme crosslinking to form microcapsules all failed to achieve this effect. This indicates that the increased expression levels of TLR4, CR3, CD80, and CD86 are achieved through the combined effect of the above conditions; the absence of any one of these conditions prevents the achievement of this effect. This suggests that TG enzyme-crosslinked composite microcapsules (product B) can upregulate the expression of Toll-like receptor 4 (TLR4) and complement receptor 3 (CR3) on the surface of macrophages, thereby enhancing the recognition and response to Cordyceps sinensis polysaccharide and amplifying the immune signal transduction pathway. Furthermore, it indicates that TG enzyme-crosslinked composite microcapsules (product B) can enhance the maturation and antigen presentation function of dendritic cells (DCs), which participate in the immune-enhancing effect of Cordyceps sinensis polysaccharide, forming a positive feedback loop of "innate immunity-adaptive immunity" and significantly enhancing the overall immune response. Cordyceps sinensis polysaccharide is slowly released in the intestine as a wall material, continuously activating TLR4; glycosylated modified CK is released at specific sites as a core material, simultaneously activating NF-κB. The two pathways overlap and produce a cascade amplification. Only when the polysaccharide wall material + glycosylated modified CK core material + TG enzyme cross-linking are integrated can the immune activity be maximized.

[0069] Example 3: Screening of Microcapsule Wall Materials Soy protein isolate, gelatin, chitosan, and whey protein were selected as wall material component 1, and Cordyceps sinensis polysaccharide, ginseng polysaccharide, and Ganoderma lucidum polysaccharide were selected as wall material component 2. Modified rare ginsenosides from Example 1 were used as the core for microcapsule preparation. The encapsulation rate and other parameters of each group were tested using the method described in Example 2 to screen the wall material types. The grouping results are shown in Table 9. Particle size detection method: The particle size of the sample was detected using a nanoparticle size Zeta potential analyzer, and the Z-Average average particle size value was directly read using dynamic light scattering mode.

[0070] Zeta potential detection method: A nanoparticle-scale Zeta potential analyzer was used to read the Zeta potential test results of each sample using electrophoretic light scattering mode.

[0071] Drug loading detection method: The drug loading content of the inner core after microcapsule rupture was detected by HPLC method as described in Example 2.

[0072] TG enzyme crosslinking degree: Using a full-wavelength microplate reader and the hydroxylamine colorimetric method, the reaction temperature was set to 37℃ and pH 6.0. The absorbance difference between the sample and the blank control group was measured at a wavelength of 525nm. The proportion of remaining free glutamine residues was calculated, and the TG enzyme crosslinking degree was obtained by subtracting this proportion from 1.

[0073] Table 9 Grouping of Microcapsule Wall Material Types

[0074] The experimental results are shown in Table 9 below: Table 10 Screening Results of Microcapsule Wall Material Types

[0075] According to the experimental data in Table 10, the encapsulation efficiency was poor when only one substance was selected as the wall material for microcapsule preparation. When the microcapsules were prepared by combining one substance from wall material component 1 and wall material component 2 to form a composite wall material, the microcapsules obtained by cross-linking the CPS + SPI composite wall material with TG enzyme showed the highest encapsulation efficiency, which was significantly better than other combinations of composite wall materials. Therefore, the W8 group, which uses soy protein isolate and Cordyceps sinensis polysaccharide as the composite wall material, is the best choice. Other indicators, except for the encapsulation efficiency, also showed a basically the same trend, indicating that the composite wall material composed of soy protein isolate and Cordyceps sinensis polysaccharide is the optimal wall material choice under this system, which can significantly improve the encapsulation efficiency and various properties of the microcapsules.

[0076] The relative bioavailability of each group of active ingredients and their release in simulated gastric and intestinal fluids were detected and studied according to the method in Example 2. The experimental results are shown in Table 11. Table 11. Results of relative bioavailability and release in simulated gastric and intestinal fluids.

[0077] The results of relative bioavailability and release in simulated gastric and intestinal fluids showed that CPS and SPI, as composite wall materials, can enhance the bioavailability of both CPS and ginseng rare saponin modified substances, exhibit minimal degradation in gastric fluid, and exert a synergistic effect in intestinal fluid release. Using either wall material alone, or replacing it with other commonly used wall materials or medicinal and edible polysaccharides, could not achieve this effect. This indicates that the microcapsules form a specific "wall material-core material" synergistic release model. The release process of this model includes the following stages: Stage 1 (stomach, pH 1.2): β-(1→3)-glucan in the CPS molecule forms a tight gel layer under acidic conditions, the SPI-TG enzyme cross-linking network remains intact, the microcapsule volume shrinks, effectively preventing core material leakage; Stage 2 (upper intestine, pH 6.0-6.8) CPS molecules begin to swell, the gel layer gradually loosens, the SPI-TG enzyme network is partially degraded by trypsin, the microcapsule size gradually decreases, and rare saponins (CK, Rg3, Rh2) begin to diffuse and be released from the microcapsules. Simultaneously, the CPS wall material itself begins to dissolve, releasing immunologically active polysaccharide fragments; the third stage (lower intestine, pH...) 6.8-7.4): The microcapsules completely disintegrate, releasing all core and residual wall polysaccharides. At this point, rare saponins and CPS fragments form a high-concentration "synergistic microenvironment" in the intestinal tract. CPS promotes the intestinal absorption of rare saponins. The β-(1→3)-glucan component in CPS binds to Dectin-1 receptors on the surface of intestinal M cells, triggering endocytosis and transport. Simultaneously, it temporarily increases the permeability of tight junctions between intestinal epithelial cells (reversible opening), increasing intestinal mucosal permeability and thus promoting the transmembrane absorption of rare saponins. As a prebiotic, CPS promotes the proliferation of beneficial intestinal bacteria (such as Bifidobacteria and Lactobacillus), improving the intestinal microecological environment. These beneficial bacteria can further convert incompletely converted saponin precursors into more active rare saponins, creating a "secondary biotransformation" effect. In intestinal digestive fluids, CPS can form a mixed micelle system with bile salts and phospholipids, increasing the concentration of hydrophobic rare saponins (such as Rh2). The CPS improves water solubility and bioavailability (logP≈5.14), thereby enhancing its absorption efficiency; the oligosaccharide fragments in CPS inhibit the function of drug efflux pumps such as P-glycoprotein (P-gp), reducing the intestinal efflux of rare saponins and increasing their accumulation in intestinal epithelial cells; on the other hand, under this "synergistic microenvironment", the relative bioavailability of CPS is further improved.

[0078] Example 4: Screening and optimization of wall material and core combination The various cases of using two active substances as wall materials or cores were studied, and the screening and optimization grouping of wall material and core combinations are shown in Table 12: Table 12 Screening and Optimization Grouping of Wall Material and Core Combinations

[0079] The experimental results are shown in Table 13. If soy protein isolate is used alone as the wall material to encapsulate ginseng rare saponin modifiers or CPS, the relative bioavailability and immunomodulatory activity of the two active substances are lower than those of the composite wall material. Furthermore, a large amount of ginseng rare saponins are released and degraded in the gastric juice stage, preventing the simultaneous large-scale release of the two active substances in the intestinal juice. However, when soy protein isolate and CPS are used as the composite wall material to encapsulate ginseng rare saponin modifiers, the relative bioavailability of the two active substances is significantly increased, and both active substances (including ginseng rare saponins and CPS) are simultaneously released in large quantities in the intestinal juice, indicating that they can synergistically exert their effects in the intestine simultaneously. In addition, the immunomodulatory activity of the microcapsules is also significantly increased, indicating that this specific "wall material-core material" synergistic release model forms a high-concentration "synergistic microenvironment" in the intestinal tract after synchronous release, effectively promoting immunomodulatory activity. However, using ginseng rare saponins and soy protein isolate as wall materials and CPS as the core, or using ginseng rare saponins, CPS, and soy protein isolate as wall materials, cannot achieve the aforementioned beneficial effects. This indicates that in the unique "wall material-core material" synergistic release model formed by soy protein isolate, CPS as the composite wall material, and ginseng rare saponin modifiers as the inner core, CPS promotes the intestinal absorption of rare saponins, while ginseng rare saponin modifiers promote the intestinal absorption of CPS. Microcapsules containing the above two active ingredients enhance immunomodulatory activity.

[0080] Table 13 Screening Results of Wall Material and Core Combinations

[0081] Experimental Example 5: Screening of Enzyme Types in Enzymatic Directed Glycosylation The enzymes listed in the table below were selected for optimization and screening (30g of maltodextrin DE10-15 was used as the glycosyl donor in each group, and other reaction conditions were the same). The yield of glycosylated products in each group was used to evaluate the effectiveness of different types of enzymes in the enzymatic directional glycosylation of the starting material Compound K (CK technical / substrate CK). According to the HPLC method in Example 2, the following indicators were detected based on the peak positions of different substances.

[0082] The detection methods for each indicator are as follows: Experimental Methods: 10.0 g of high-purity ginsenoside Compound K (CK technical grade, purity ≥98%) was dissolved in 100 mL of 20% (v / v) ethanol aqueous solution. 30 g of maltodextrin (DE10-15) was added as a glycosyl donor, and 800 mL of phosphate buffer (50 mM, pH 6.5) was added. The mixture was stirred to form a homogeneous suspension. The corresponding enzymes were added according to the groups listed in Table 14, with a uniform enzyme dosage of 15 U / g substrate CK. The reaction temperature was adjusted to the optimal temperature (45°C) for each enzyme, and the reaction was carried out under light with stirring until the reaction time listed in Table 14 was reached. After the reaction, the temperature was raised to 90°C and held for 10 min to inactivate the enzymes. The mixture was centrifuged at 8000 rpm for 15 min, and the supernatant was collected for HPLC analysis.

[0083] HPLC analysis of glycosylated products: A C18 reversed-phase column (250 mm × 4.6 mm, 5 μm) was used; mobile phase A was water, and mobile phase B was acetonitrile; gradient elution program: 0–5 min 20% B, 5–30 min 20% → 60% B, 30–40 min 60% → 90% B, 40–45 min 90% B; flow rate 1.0 mL / min; detection wavelength 203 nm; column temperature 30°C; injection volume 20 μL. A series of standard solutions were prepared using Rb1, CK, Rg3, Rh2, and Rd standards (Sigma-Aldrich) to establish a standard curve for quantification. The detection methods for each index are as follows: (1) Rb1 conversion rate: Using ginsenoside Rb1 as substrate, the remaining amount of Rb1 was detected by HPLC after the reaction. The conversion rate (%) = (initial Rb1 peak area - remaining Rb1 peak area) / initial Rb1 peak area × 100%.

[0084] (2) Monosaccharide CK selectivity: expressed as the percentage of the peak area of ​​the target glycosylation product (monosaccharide CK) to the total peak area of ​​all glycosylation products, reflecting the directional selectivity of the enzyme-catalyzed reaction.

[0085] (3) Rg3 and Rh2 yield: The amount of Rg3 and Rh2 generated in the reaction solution was detected by HPLC and expressed in mg / mL. Rh2 is a desugaring byproduct generated by the further hydrolysis of the C-3 sugar chain in the enzymatic reaction of CK. The lower the yield, the better the control of the side reaction.

[0086] (4) Evaluation of monosaccharide products: The degree of glycosylation is evaluated by the amount of Rd generated and the total amount of intermediates. If the amount of Rd generated is too low, it indicates excessive glycosylation, and if it is too high, it indicates insufficient glycosylation.

[0087] (5) Byproduct ratio: expressed as the percentage of the peak area of ​​all non-target products in the HPLC chromatogram to the total peak area.

[0088] Improving the glycosylation yield has significant practical implications. A higher glycosylation yield means that more starting material Compound K (CK technical grade / substrate CK) molecules are successfully modified into a soluble form, i.e., successfully converted into soluble glycosylated modified CK (product A, solubility 852.4 mg / L, 167 times higher than CK technical grade 5.1 mg / L). This is more conducive to subsequent microencapsulation and in vivo application, and directly determines the content of active ingredients and functional application value of the final product. In the table, the glycosylation modification CK (product A / monosaccharified CK) (mg / mL) refers to the total concentration of all substances containing the CK core (including unreacted substrate CK and glycosylated modified CK products) in the supernatant of the centrifuged reaction solution. It is calculated by summing the peak areas at the characteristic absorption wavelength of CK using HPLC and substituting them into the CK standard curve, reflecting the enzyme's directional glycosylation conversion efficiency of the CK substrate. The total yield of rare saponins (mg / mL) refers to the total concentration of all rare saponins (glycosylated modified CK (product A / monosaccharified CK) + Rh2 + Rg3 + Rd + other rare saponins) in the supernatant of the reaction solution. It is calculated by summing the values ​​after quantifying each standard separately, reflecting the enzyme's overall catalytic production capacity. The difference between the two is the amount of non-CK rare saponin byproducts generated; the smaller the difference, the better the enzyme's directional selectivity. The higher the yield of glycosylated modified CK and the larger its ratio to the total yield of rare saponins, the better the side reaction control is while maintaining high conversion efficiency, which is more conducive to obtaining high-purity target products.

[0089] Table 14 Grouping of Enzyme Types in Enzymatic Directed Glycosylation

[0090] The experimental results are shown in Tables 15 and 16. Based on the results of various indicators, using the enzymes in group E2 for enzymatic directional glycosylation can produce more glycosylated products and generate fewer impurities, which is better than other enzymes.

[0091] Table 15 Results of enzyme screening in enzymatic targeted glycosylation

[0092] Table 16 Comparison of enzymatic directional glycosylation effect in group E2 with other groups

[0093] Microcapsules were prepared using the method described in Example 1 (except for the choice of transglycosylase, all other conditions remained the same). The method described in Example 2 was used to study the relative bioavailability, intestinal release, and immunomodulatory activity of microcapsules prepared with different transglycosylases. The experimental results are shown in Table 17. The E2 group had the highest relative bioavailability and was almost completely released into the intestine. The microcapsules prepared in the E2 group also had the highest TLR4 expression level, indicating that it had the best immunomodulatory activity. Other immunomodulatory activity-related indicators also showed the same trend. However, the above effects could not be achieved by using other transglycosylases. This indicates that different transglycosylases have a significant impact on the bioavailability, intestinal fluid release, and immunomodulatory activity of the active substances in the final microcapsules. Only when Aspergillus niger β-glucosidase of the E2 group was the most effective result achieved.

[0094] Table 17 Effects of different transglycosylases on microcapsule properties

[0095] While the present invention has been disclosed above, it is not limited thereto. Any person skilled in the art can make various modifications and alterations without departing from the spirit and scope of the invention; therefore, the scope of protection of the present invention should be determined by the scope defined in the claims.

Claims

1. A microcapsule encapsulating insoluble rare ginsenosides, characterized in that, The wall material of the microcapsules includes protein-based wall materials and active polysaccharides that are both medicinal and edible.

2. The microcapsule as described in claim 1, characterized in that, The protein-based wall material is selected from one or more of soy protein isolate, gelatin, whey protein, albumin, pea protein, broad bean protein, and peanut protein; the medicinal and edible active polysaccharide is selected from one or more of Cordyceps sinensis polysaccharide, ginseng polysaccharide, astragalus polysaccharide, oat β-glucan, and Ganoderma lucidum polysaccharide.

3. The microcapsule as described in claim 2, characterized in that, The protein-based wall material is soybean protein isolate; the medicinal and edible active polysaccharide is Cordyceps sinensis polysaccharide.

4. The microcapsule as described in claim 3, characterized in that, The wall material of the microcapsules is encapsulated with insoluble rare ginsenosides through enzymatic covalent cross-linking via transglutaminase.

5. The microcapsule as described in claim 4, characterized in that, The insoluble ginsenoside modified by the microcapsule is formed by the catalysis of transglycosylase to attach groups on the glycosyl donor to the ginsenoside.

6. The microcapsule as described in claim 5, characterized in that, The transglycosylase is selected from one or more of cyclodextrin glucosyltransferase, starch sucrase, or β-glucosidase.

7. A method for preparing microcapsules encapsulating insoluble rare ginsenoside modifiers, characterized in that, The preparation method includes the following steps: Enzymatic directional glycosylation: Using transglycosylase, groups on the glycosyl donor are catalyzed to attach to ginsenosides, forming insoluble rare ginsenoside modified products; TG enzymatic covalent crosslinking: After shearing and emulsifying protein wall materials and medicinal and edible active polysaccharides, insoluble rare ginseng saponins are encapsulated by transglutaminase covalent crosslinking.

8. The preparation method according to claim 7, characterized in that, The transglycosylation enzyme is selected from one or more of cyclodextrin glucosyltransferase, starch sucrase, or β-glucosidase; the protein wall material is soybean protein isolate; and the medicinal and edible active polysaccharide is Cordyceps sinensis polysaccharide.

9. Use of a microcapsule as described in any one of claims 1 to 6, or a microcapsule prepared by the method described in claim 7 or 8, in improving the performance of an active ingredient, wherein the improved performance includes: The solubility of rare ginsenosides is improved; The bioavailability of rare ginsenosides and cordyceps polysaccharides in vivo is improved; Rare ginsenosides and cordyceps polysaccharides are released upon reaching the small intestine and colon.

10. Use of a microcapsule as described in any one of claims 1 to 6, or a microcapsule prepared by the method described in claim 7 or 8, in the preparation of a drug for enhancing immunomodulatory activity.